Skip to main content

Table 4 Adverse events of any grade seen in > 5% of patients in either protocol arm

From: TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

  Letrozole, n = 25 Letrozole/Bevacizumab, n = 50
  Number of patients (percent)
Adverse events Any grade Grade ≥ 3 Any grade Grade ≥ 3
 Hot flashes 7 (28) 0 9 (18) 0
 Arthralgia/joint stiffness 6 (24) 2 (8) 13 (26) 2 (4)
 Fatigue 4 (16) 0 7 (14) 1 (2)
 Myalgias/cramps 3 (12) 0 3 (6) 0
 Nausea/vomiting 2 (8) 0 1 (2) 0
 Night sweats 2 (8) 0 2 (4) 0
 Mood swings/anxiety/agitation 1 (4) 0 3 (6) 0
 Vaginal dryness 1 (4) 0 3 (6) 0
 Hypertension 1 (4) 0 16 (32) 4 (8)
 Hemorrhagic and thrombotic events 0 0 8 (16) 3 (6)
 Headache 1 (4) 0 7 (14) 0
 Proteinuria 0 0 5 (10) 2 (4)
 Dyspnea 1 (4) 0 5 (10) 0
 Skin (rash, discoloration, pruritus) 2 (8) 0 4 (8) 0
 Lower extremity edema 0 0 3 (6) 0